Last reviewed · How we verify
Cyclo-Progynova
Cyclo-Progynova is a cyclical hormone replacement therapy combining estrogen and progestin to replace declining hormones in menopausal women.
Cyclo-Progynova is a cyclical hormone replacement therapy combining estrogen and progestin to replace declining hormones in menopausal women. Used for Menopausal vasomotor symptoms (hot flashes, night sweats), Menopausal genitourinary symptoms, Osteoporosis prevention in postmenopausal women.
At a glance
| Generic name | Cyclo-Progynova |
|---|---|
| Sponsor | El Shatby University Hospital for Obstetrics and Gynecology |
| Drug class | Hormone replacement therapy (HRT) |
| Target | Estrogen receptor, Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Gynecology / Endocrinology |
| Phase | Phase 3 |
Mechanism of action
The drug delivers alternating doses of estradiol (estrogen) and norgestrel (progestin) in a 21-day cycle to mimic natural hormonal fluctuations. This cyclical regimen helps alleviate vasomotor symptoms (hot flashes, night sweats) and other menopausal symptoms while providing endometrial protection through the progestin component.
Approved indications
- Menopausal vasomotor symptoms (hot flashes, night sweats)
- Menopausal genitourinary symptoms
- Osteoporosis prevention in postmenopausal women
Common side effects
- Breast tenderness
- Headache
- Nausea
- Vaginal bleeding/spotting
- Fluid retention
Key clinical trials
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (PHASE1)
- Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR (PHASE2)
- A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants (PHASE1)
- Validating and Assessing Reliability
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) (PHASE1)
- A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age (PHASE1)
- Adaptions and Resiliency to Multi-Stressor OpeRations (PHASE4)
- International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclo-Progynova CI brief — competitive landscape report
- Cyclo-Progynova updates RSS · CI watch RSS
- El Shatby University Hospital for Obstetrics and Gynecology portfolio CI